1. Academic Validation
  2. Neutrophil elastase inhibitors as treatment for COPD

Neutrophil elastase inhibitors as treatment for COPD

  • Expert Opin Investig Drugs. 2002 Jul;11(7):965-80. doi: 10.1517/13543784.11.7.965.
Hiroyuki Ohbayashi 1
Affiliations

Affiliation

  • 1 Internal Medicine II, Nagoya University School of Medicine, 65, Tsurumai-cho, Showa-ku, Nagoya city, 466-8550, Japan. ohbayasi@nn.iij4u.or.jp
Abstract

Chronic obstructive pulmonary disease, characterised by a slowly progressive, irreversible airways limitation, is a major worldwide cause of chronic morbidity and mortality. The imbalance between human neutrophil Elastase and endogenous antiproteases may cause excess human neutrophil Elastase in pulmonary tissues, which may be considered a major pathogenic factor in chronic obstructive pulmonary disease. Great effort has been devoted to finding a method to restore the balance, resulting in the discovery of potent two-typed small-molecular-weight human neutrophil Elastase inhibitors. In the application of chronic obstructive pulmonary disease therapy, the human neutrophil Elastase inhibitors mainly focused upon include ONO-5046, MR-889, L-694,458, CE-1037, GW-311616 and TEI-8362 as the acyl-enzyme inhibitors; and ONO-6818, AE-3763, FK-706, ICI-200,880, ZD-0892 and ZD-8321 as the transition-state inhibitors. In this review, various problems that remain to be solved in the clinical use of human neutrophil Elastase inhibitors are discussed.

Figures
Products